Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2012 Mar 1;21(123):8-18.
doi: 10.1183/09059180.00008211.

REVEAL: a contemporary US pulmonary arterial hypertension registry

M D McGoon  1 , D P Miller
Affiliations
Multicenter Study

REVEAL: a contemporary US pulmonary arterial hypertension registry

M D McGoon et al. Eur Respir Rev. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Statement of Interest

M.D. McGoon's institution has received research funding from Medtronic and Gilead for studies related to pulmonary hypertension in which he was primary investigator. He has served on advisory, steering and/or endpoint/DSMB committees for Actelion, Gilead, Lung LLC, GSK and Medtronic. He has received honoraria for speaking at conferences supported by Actelion and Gilead. D.P. Miller is an employee of ICON Late Phase and Outcomes Research, a division of ICON PLC. His department receives research funding from pharmaceutical companies to conduct observational research. Funding for the statistical analysis of the REVEAL study is provided by Actelion. No funding was provided for his participation in this manuscript.

Figures

Figure 1.
Figure 1.
Number of previously (n=2,555) and newly (n=960) diagnosed pulmonary arterial hypertension patients enrolled in REVEAL by year of diagnosis.
Figure 2.
Figure 2.
Inclusion characteristics of a) previously diagnosed and b) newly diagnosed pulmonary arterial hypertension (PAH) patients enrolled in REVEAL. PVR: pulmonary vascular resistance; P̄pa: mean pulmonary artery pressure; Ppcw: pulmonary capillary wedge pressure; LVEDP: left ventricular end-diastolic pressure.
Figure 3.
Figure 3.
a) Pulmonary arterial hypertension (PAH) aetiological breakdown of REVEAL patients at enrolment. b) Breakdown of associated PAH subgroup. PPHN: persistent pulmonary hypertension of the newborn; PVOD: pulmonary veno-occlusive disease; PCH: pulmonary capillary haemangiomatosis; FPAH: familial PAH; APAH: associated PAH; IPAH: idiopathic PAH; CHD: congenital heart disease; CVD/CTD: collagen vascular disease/connective tissue disease. Reproduced from [15] with permission from the publisher.
Figure 4.
Figure 4.
Pulmonary arterial hypertension specific medication use at enrolment among previously diagnosed patients. 184 (7%) of patients were not on a prostaglandin, phosphodiesterase type-5 inhibitor or endothelin receptor antagonist. Of these, 88 were on calcium channel blockers for the treatment of pulmonary arterial hypertension.
Figure 5.
Figure 5.
1-yr survival estimates of 641 connective tissue disease-associated pulmonary arterial hypertension (CTD-APAH) patients compared with 1,251 idiopathic pulmonary arterial hypertension (IPAH) patients in REVEAL. Log rank p<0.0001. Reproduced from [22] with permission from the publisher.
Figure 6.
Figure 6.
Cox proportional hazard estimates for multivariate model of survival, limited to terms included in the final stepwise model. Parameters significantly associated with 1-yr survival include the Borg dyspnoea scale, right ventricular dysfunction, pulmonary vascular resistance (PVR) index, pulmonary capillary wedge pressure, cardiac index, mean pulmonary artery pressure and total serum bilirubin. Candidate predictor variables that were not significant at the univariable level included Tei index, vasoreactivity, race, newly diagnosed pulmonary arterial hypertension (PAH) and income. Missing Borg scale and missing PVR index were both associated with lower than average observed survival and were, therefore, considered candidate predictor variables. WHO: World Health Organization; CTD: connective tissue disease; APAH: associated PAH; PoPH: portal hypertension; FPAH: familial PAH; NYHA: New York Heart Association; 6MWD; 6-min walk distance; BNP: brain natriuretic protein; DL,CO: diffusing capacity of the lung for carbon monoxide; % pred: % predicted; RHC: right heart catheterisation; P̄ra: mean right atrial pressure. Data are presented as hazard ratio (HR) with 95% confidence level. #: reference category was NYHA/WHO functional class II or missing; : if N-terminal proBNP is available and BNP is not, cut-off points are replaced with <300 pg·mL−1 and >1,500 pg·mL−1; +: restricted to tests performed within 1 yr of enrolment, otherwise, the indicator is set to 0. Reproduced from [27] with permission from the publisher.
Figure 7.
Figure 7.
Survival estimates of patients in REVEAL using Kaplan–Meier estimates stratified by newly versus previously diagnosed patients and survival estimated by a delayed entry model accounting for truncation. The model includes all REVEAL patients but the number of patients at risk is limited to the time period during which they were followed in the study. Therefore, the first 3 months is estimated exclusively based on newly diagnosed patients and thereafter combined data from previously diagnosed patients and long-term follow-up of newly diagnosed patients. #: newly diagnosed; : previously diagnosed.
Figure 8.
Figure 8.
REVEAL pulmonary arterial hypertension (PAH) risk score. CTD: connective tissue disease; APAH: associated PAH; PoPH: portal hypertension; FPAH: familial PAH; WHO: World Health Organization; NYHA: New York Heart Association; 6MWD: 6-min walk distance; BNP: brain natriuretic peptide; PFT: pulmonary function test; RHC: right heart catheterisation; SBP: systolic blood pressure; HR: heart rate; DL,CO: diffusing capacity of the lung for carbon monoxide; % pred: % predicted; P̄ra: mean right atrial pressure; PVR: pulmonary vascular resistance. #: if N-terminal proBNP is available and BNP is not, cut-off points are replaced with <300 pg·mL−1 and >1,500 pg·mL−1. Reproduced from [31] with permission from the publisher.
See this image and copyright information in PMC

References

    1. Rich S, Dantzker DR, Ayres SM, et al. . Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107: 216–223. - PubMed
    1. Rich S, ed. Executive summary from the World Symposium on Primary Pulmonary Hypertension 1998. Evian, September 6–10, 1998. Co-sponsored by the World Health Organization.
    1. Simonneau G, Galiè N, Rubin L, et al. . Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, S5–S12. - PubMed
    1. Simonneau G, Robbins IM, Beghetti M, et al. . Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43–S54. - PubMed
    1. Stricker H, Domenighett G, Popov W, et al. . Severe pulmonary hypertension: data from the Swiss Registry. Swiss Med Wkly 2001; 131: 346–350. - PubMed

Publication types